PI Episode 1 - SUCRAID Untitled Letter

In this episode, Jason and Virginia break down the recent enforcement letter regarding Sucraid, highlighting its misleading promotional materials. The FDA has flagged two emails targeting healthcare professionals for their claims about the product's indication and presentation of safety.We dive into the details—what was wrong with the promotional emails?  And what should be done differently to ensure compliance?This conversation sheds light on the importance of accurate communication in healthcare. Let’s not forget: clarity in presenting risks is crucial for patient safety! Compliance Forward WebsiteConnect with us on LinkedIn